Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute has launched a regenerative neurology program in San José del Cabo that uses an intranasal delivery platform to move therapies toward the brain without a lumbar puncture. The institute says the approach expands options for selected neurological conditions while keeping intrathecal treatment available when needed.

Why it matters: - The new platform gives patients a non-invasive alternative to intrathecal administration for selected neurological conditions. - The approach is designed to widen treatment access for regenerative neurology while reducing the need for lumbar puncture in appropriate cases. - The launch adds another delivery route in a field where getting therapies into the brain remains a core challenge.

What happened: - Longevity Medical Institute announced the launch of its Regenerative Neurological Therapy Program in San José del Cabo, Baja California Sur, Mexico. - The program includes an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. - The institute said the platform is intended for use when clinically appropriate as an alternative to intrathecal administration. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the addition expands the institute’s ability to personalize treatment. - Dr. Sanford said patients now have access to both intrathecal and non-invasive intranasal administration.

The details: - The blood-brain barrier blocks many therapeutic compounds from reaching the central nervous system. - Intrathecal administration remains the most direct route into cerebrospinal fluid, but it requires a lumbar puncture. - The intranasal platform uses a nose-to-brain delivery technology described as one of the most extensively studied in the scientific literature. - The system is engineered to target the upper nasal cavity near the olfactory region, rather than the lower nasal passages targeted by conventional nasal sprays. - Research has shown that compounds delivered to the olfactory region may travel toward the brain through the olfactory and trigeminal nerve pathways. - The platform uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer generates microscopic aerosol droplets and delivers them gradually over several minutes. - The controlled delivery is designed to increase contact time in the olfactory region, reduce medication loss into the throat, and improve delivery consistency. - The platform is used exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes, and selected therapeutic peptides. - Treatment recommendations are made by the institute’s multidisciplinary physician team after a comprehensive neurological evaluation. - The evaluation may include advanced imaging, laboratory testing, neurological examination, and review of the patient’s medical history. - The institute’s broader neurological program also includes intravenous regenerative therapies, intrathecal administration in its fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging, and multidisciplinary physician care. - The company’s website for the program is More information.

Between the lines: - The launch positions intranasal delivery as a lower-burden option for patients who may not need direct spinal administration. - The institute is framing the platform as a precision-medicine tool, with delivery method chosen based on diagnosis, clinical findings, and treatment goals. - Human research on MSCs and MSC-derived exosomes has reported encouraging findings across several neurological disorders, but the release does not claim definitive efficacy. - Dr. Sanford said published human evidence supporting the safety of MSC-based therapies is encouraging. - The institute also says larger randomized clinical trials are still needed to define which patients benefit most and how durable responses are.

What's next: - Longevity Medical Institute said regenerative neurological therapies remain an evolving area of translational medicine. - The institute is expected to continue using physician evaluation, published evidence, patient-specific factors, and clinical judgment to guide treatment decisions. - Future research will need to clarify patient selection and the long-term durability of responses.

The bottom line: - Longevity Medical Institute is betting that a non-invasive nose-to-brain delivery system can expand regenerative neurology options without replacing intrathecal care when the more direct route is still needed.